Technical Analysis for NVCR - NovoCure Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 3.11% | |
| Crossed Above 200 DMA | Bullish | 3.11% | |
| Pocket Pivot | Bullish Swing Setup | 3.11% | |
| Gapped Up | Strength | 3.11% | |
| Up 3 Days in a Row | Strength | 3.11% | |
| 20 DMA Resistance | Bearish | 9.47% | |
| Pocket Pivot | Bullish Swing Setup | 9.47% | |
| Oversold Stochastic | Weakness | 9.47% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 14.18% | |
| Pocket Pivot | Bullish Swing Setup | 14.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Up 2% | about 1 hour ago |
| 2x Volume Pace | about 2 hours ago |
| 1.5x Volume Pace | about 2 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/27/2023
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Pancreatic Cancer Blastoma Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Brain Cancer Helio Metastases Mesothelioma
Classification
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Pancreatic Cancer Blastoma Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Brain Cancer Helio Metastases Mesothelioma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 120.03 |
| 52 Week Low | 56.055 |
| Average Volume | 640,068 |
| 200-Day Moving Average | 76.39 |
| 50-Day Moving Average | 67.77 |
| 20-Day Moving Average | 75.63 |
| 10-Day Moving Average | 76.88 |
| Average True Range | 3.33 |
| RSI (14) | 62.26 |
| ADX | 24.18 |
| +DI | 32.76 |
| -DI | 21.01 |
| Chandelier Exit (Long, 3 ATRs) | 73.62 |
| Chandelier Exit (Short, 3 ATRs) | 71.48 |
| Upper Bollinger Bands | 83.91 |
| Lower Bollinger Band | 67.35 |
| Percent B (%b) | 0.74 |
| BandWidth | 21.89 |
| MACD Line | 2.12 |
| MACD Signal Line | 2.67 |
| MACD Histogram | -0.5468 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 89.09 | ||||
| Resistance 3 (R3) | 88.06 | 83.84 | 87.50 | ||
| Resistance 2 (R2) | 83.84 | 81.40 | 84.36 | 86.96 | |
| Resistance 1 (R1) | 81.68 | 79.90 | 82.76 | 82.71 | 86.43 |
| Pivot Point | 77.46 | 77.46 | 78.00 | 77.98 | 77.46 |
| Support 1 (S1) | 75.30 | 75.02 | 76.38 | 76.33 | 72.61 |
| Support 2 (S2) | 71.08 | 73.52 | 71.60 | 72.08 | |
| Support 3 (S3) | 68.92 | 71.08 | 71.55 | ||
| Support 4 (S4) | 69.95 |
